Current reports

Current report no 9/2026 – Execution of an Agreement with Pharmalink for the Commercialization of Reduzek (semaglutide) in Selected Gulf Countries

2026-06-08

Current Report No. 8/2026 – Allocation of Series A Subscription Warrants to Eligible Participants under the Management Incentive Program

2026-06-03

Current Report No. 7/2026 – Notice of Convening the Annual General Meeting of Celon Pharma S.A. on June 24, 2026, Together with Draft Resolutions

2026-05-29

Current Report No. 6/2026 – Four Celon Pharma S.A. Projects Selected for Funding under a Competition Announced by the Medical Research Agency

2026-05-06

Current report 5/2026 – Execution of Amendments to Agreements Concerning Cooperation with Tang Capital

2026-03-16

Current Report No. 4/2026 – Execution of a Financing Agreement by the Issuer’s Subsidiary with the European Bank for Reconstruction and Development

2026-03-09

Current Report No. 3/2026 – Resignation and Appointment of a Management Board Member of Celon Pharma S.A.

2026-02-27

Current Report No. 2/2026 – Summary of the FDA Type B Meeting for CPL’36 in the Treatment of Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease (PD-LID)

2026-02-09

Current Report No. 1/2026 – Dates of publication of periodic reports in 2026

2026-01-26